<DOC>
	<DOCNO>NCT00243321</DOCNO>
	<brief_summary>The principal objective study demonstrate patient safely receive combine High Dose Rate brachytherapy Intensity-Modulated Radiation Therapy without experience treatment limit toxicity .</brief_summary>
	<brief_title>High Dose-Rate Brachytherapy and/or Intensity Modulated External Beam Radiation Therapy Prostate Cancer</brief_title>
	<detailed_description>Patients receive single High Dose Rate brachytherapy dose 6 Gy prostate , follow 61 Gy deliver prostate nearby tissue use Intensity-Modulated Radiation Therapy 28 treatment .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>TRUS biopsy proven adenocarcinoma prostate Pretreatment PSA &lt; 30 ng/ml Gleason 's sum &lt; 8 clinical stage T1 T2a , b . patient lowintermediate risk disease beyond prostate normal liver function patient begin hormone therapy Karnofsky Performance score &gt; 80 acceptable anesthesia risk determine routine preoperative screening VCUHS Diagnostic Testing Clinic pubicarch interference regional disease ( evidence metastatic disease patient whose PSA great 10 ng/ml , Gleason 's sum great 6 , Tstage great T2a . Patients high risk distant disease ( PSA &gt; 30 ng/ml , Gleason 's sum &gt; 8 clinical stage &gt; T2c ) , clinically involved seminal vesicle extension beyond prostate capsule history inflammatory bowel disease require steroid cytotoxic therapy collagen vascular disease uncontrolled poorly control hypertension uncontrolled poorly control diabetes mellitus history cancer skin cancer within five year initiation protocol treatment history pelvic irradiation require routine use warfarin</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>brachytherapy</keyword>
	<keyword>intensity-modulated radiation therapy</keyword>
	<keyword>prostate specific antigen</keyword>
</DOC>